Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
By G. Schwartz, A. Olsson, M. Ezekowitz, P. Ganz, M. Oliver, D. Waters, Andreas H. Zeiher, Bernard R. Chaitman, S. Leslie, Theresa P. Stern. Journal of the American Medical Association (JAMA), 2001
1,159 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/e9a9c25353ceec8ee649ece10a5f973f880c91c2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- D. Yellon
- Harvey D. White
- D. Hausenloy
- I. Graham
- Robert M. Califf
- J. Blumenthal
- E. Braunwald
- Allan S. Jaffe
In Surgery
- I. Graham
- Harvey D. White
- M. Manoharan
- Robert Langer
- Robert M. Califf
- E. Braunwald
- Jay D. Horton
- V. Mohanraj
Citations in the corpus
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “8 mmol/L ( 70 mg/dL).(466,467) The early drug treatment should be combined with effective lifestyle changes and particularly dietary counselling after hospital discharge.”
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates (2008, background): “Finally, the acute onset of LDLc lowering obtained with PCSK9 siRNAs could prove beneficial in a subset of patients who suffer an acute myocardial infarction where the rapid onset lowering of LDLc may be desirable (27).”
- Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. (2004, background): “05).(5) No early differences in mortality or MI were evident in MIRACL, but rehospitalization for recurrent ischemia was significantly reduced—a finding that is in contrast to the A to Z trial, in which no effect of aggressive statin therapy was observed for the end point of readmission for ACS.”
- New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. (2004, background): “Despite studies reporting benefit from the early administration of statins following an acute myocardial infarction [126,127], as yet no study has been undertaken which examines whether these drugs offer cardio-protection when given during the first few minutes of reperfusion following an acute myoc”